The Phase I study will be a dose escalation trial involving up to 50 patients with hematological malignancies. The trial will evaluate safety, pharmacokinetic and pharmacodynamic properties of SNX-5422. This clinical trial will be conducted at Vanderbilt University in Nashville, Tennessee and at the University of Pittsburg Cancer Institute in Pittsburg, Pennsylvania.
SNX-5422 is a totally synthetic small molecule delivered orally and was discovered internally using Serenex’s proprietary chemoproteomics technology platform. In pre-clinical studies SNX-5422 has demonstrated strong efficacy in multiple tumor models as a single agent and in combination with other cancer therapies.
Richard Kent, president and CEO of Serenex, said: “The hematology trial will enable us to take a closer look at biomarkers and early signals of anti-tumor activity in patients fighting hematological cancers.”